Risk Diversification and Mutual Synergies through the Hybrid Development of iPS Drug Discovery and Regenerative Medicine
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
1 other company's latest entry also says "Restated".
- FY2025RestatedAnnual report
「By developing a hybrid business combining iPS drug discovery, and regenerative medicine that treats injuries by directly transplanting cells into damaged parts of the human body, we will diversify business risk and stimulate each business by sharing technology, know-how and other resources between them.」
The company maintains its policy of hybrid development of iPS drug discovery and regenerative medicine to diversify risk and share technology and know-how. - FY2024RestatedAnnual report
「By developing a hybrid business combining iPS drug discovery, and regenerative medicine that treats injuries by directly transplanting cells into damaged parts of the human body, we will diversify business risk and stimulate each business by sharing technology, know-how and other resources between them.」
The company reiterates its policy of developing iPS drug discovery and regenerative medicine as a hybrid business to diversify risk and share technology and know-how. - FY2023First statedAnnual report
「By developing a hybrid business combining iPS drug discovery, and regenerative medicine that treats injuries by directly transplanting cells into damaged parts of the human body, we will diversify business risk and stimulate each business by sharing technology, know-how and other resources between them.」
The company first explicitly stated its intention to develop drug discovery and regenerative medicine in parallel, diversify business risk and share technology and know-how.